Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

Roeland Zoutendijk; Jurrien Gp Reijnders; Fabien Zoulim; Ashley Brown; David J Mutimer; Katja Deterding; Wolf Peter Hofmann; Joerg Petersen; Massimo Fasano; Maria Buti; Thomas Berg; Bettina E Hansen; Milan J Sonneveld; Heiner Wedemeyer; Harry L A Janssen; VIRGIL Surveillance Study Group

doi:10.1136/gutjnl-2012-302024

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

Roeland Zoutendijk
, Jurrien Gp Reijnders
, Fabien Zoulim
, Ashley Brown
, David J Mutimer
, Katja Deterding
, Wolf Peter Hofmann
, Joerg Petersen
, Massimo Fasano
, Maria Buti
, Thomas Berg
, Bettina E Hansen
, Milan J Sonneveld
, Heiner Wedemeyer
, Harry L A Janssen
, VIRGIL Surveillance Study Group

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

126 Citations (Scopus)

Abstract

Entecavir (ETV) is a potent inhibitor of viral replication in chronic hepatitis B and prolonged treatment may result in regression of fibrosis. The aim of this study was to investigate the effect of ETV on disease progression.

Original language	English
Pages (from-to)	760-5
Number of pages	6
Journal	Gut
Volume	62
Issue number	5
DOIs	https://doi.org/10.1136/gutjnl-2012-302024
Publication status	Published - May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1136/gutjnl-2012-302024

Cite this

Zoutendijk, R., Reijnders, J. G., Zoulim, F., Brown, A., Mutimer, D. J., Deterding, K., Hofmann, W. P., Petersen, J., Fasano, M., Buti, M., Berg, T., Hansen, B. E., Sonneveld, M. J., Wedemeyer, H., Janssen, H. L. A., & VIRGIL Surveillance Study Group (2013). Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 62(5), 760-5. https://doi.org/10.1136/gutjnl-2012-302024

@article{2528a30b33554316b13513d11576c1da,

title = "Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis",

abstract = "Entecavir (ETV) is a potent inhibitor of viral replication in chronic hepatitis B and prolonged treatment may result in regression of fibrosis. The aim of this study was to investigate the effect of ETV on disease progression.",

author = "Roeland Zoutendijk and Reijnders, \{Jurrien Gp\} and Fabien Zoulim and Ashley Brown and Mutimer, \{David J\} and Katja Deterding and Hofmann, \{Wolf Peter\} and Joerg Petersen and Massimo Fasano and Maria Buti and Thomas Berg and Hansen, \{Bettina E\} and Sonneveld, \{Milan J\} and Heiner Wedemeyer and Janssen, \{Harry L A\} and \{VIRGIL Surveillance Study Group\}",

year = "2013",

month = may,

doi = "10.1136/gutjnl-2012-302024",

language = "English",

volume = "62",

pages = "760--5",

journal = "Gut",

issn = "1468-3288",

publisher = "BMJ Publishing Group",

number = "5",

}

Zoutendijk, R, Reijnders, JG, Zoulim, F, Brown, A, Mutimer, DJ, Deterding, K, Hofmann, WP, Petersen, J, Fasano, M, Buti, M, Berg, T, Hansen, BE, Sonneveld, MJ, Wedemeyer, H, Janssen, HLA & VIRGIL Surveillance Study Group 2013, 'Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis', Gut, vol. 62, no. 5, pp. 760-5. https://doi.org/10.1136/gutjnl-2012-302024

TY - JOUR

T1 - Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

AU - Zoutendijk, Roeland

AU - Reijnders, Jurrien Gp

AU - Zoulim, Fabien

AU - Brown, Ashley

AU - Mutimer, David J

AU - Deterding, Katja

AU - Hofmann, Wolf Peter

AU - Petersen, Joerg

AU - Fasano, Massimo

AU - Buti, Maria

AU - Berg, Thomas

AU - Hansen, Bettina E

AU - Sonneveld, Milan J

AU - Wedemeyer, Heiner

AU - Janssen, Harry L A

AU - VIRGIL Surveillance Study Group

PY - 2013/5

Y1 - 2013/5

N2 - Entecavir (ETV) is a potent inhibitor of viral replication in chronic hepatitis B and prolonged treatment may result in regression of fibrosis. The aim of this study was to investigate the effect of ETV on disease progression.

AB - Entecavir (ETV) is a potent inhibitor of viral replication in chronic hepatitis B and prolonged treatment may result in regression of fibrosis. The aim of this study was to investigate the effect of ETV on disease progression.

U2 - 10.1136/gutjnl-2012-302024

DO - 10.1136/gutjnl-2012-302024

M3 - Article

C2 - 22490523

SN - 1468-3288

VL - 62

SP - 760

EP - 765

JO - Gut

JF - Gut

IS - 5

ER -

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this